The small number of carriers reduced our ability to study the effects of the mutation on the development of CBC; and accordingly, we could not exclude the possibility that the CHEK2*1100delC mutation is associated with modest increases in risk. The gene discussed is CHEK2; the disease is complete blood cell count.